BioPharma
CRISPR and Gene Editing: Next-Gen Manufacturing Impacts
The pharmaceutical and biotechnology industries are experiencing a profound technological revolution driven by CRISPR-Cas9 and emerging gene editing technologies that fundamentally alter how therapeutic agents...
BioPharma
Precision Medicine Manufacturing: From Large-Scale to Patient-Centric Production
The pharmaceutical industry is experiencing a fundamental shift away from the traditional “blockbuster drug” model toward increasingly sophisticated precision medicine manufacturing strategies that prioritize individual...
BioPharma
In Silico and Virtual Trials: Revolutionizing Drug Development
Drug development is entering an era of radical transformation as pharmaceutical companies embrace virtual trials and in silico methodologies to reimagine the clinical research process....
BioPharma
AI-Enabled Supply Chain Resilience in Pharmaceutical Manufacturing
Pharmaceutical supply chains are fundamentally evolving as global disruptions, regulatory demands, and patient expectations converge to redefine how drugs reach the market. In today’s environment,...
BioPharma
FDA Looking to Lower Drugs Cost for All Americans
The Food and Drug Administration is looking to speed the development when it comes to biosimilars and has announced new guidelines, which would no longer...
BioPharma
GSK Licences COPD Drug from Empirico for $85 Million Upfront
In just a space of 24 hours, GSK, in its second pipeline-expanding deal, has gone on to license the rights to a drug for chronic...
BioPharma
CDMO Market for AAV Therapies to Hit $2.566 Billion By 2033
With a focus on Adeno-Associated Virus (AAV), the worldwide market for Contract Development and Manufacturing Organizations (CDMMOs) that biomanufacture cell and gene therapies has shown...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.